Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

证券代码：688098 证券简称：申联生物 公告编号：2026-002 申联生物医药（上海）股份有限公司 关于取得《兽药GMP证书》和《兽药生产许可证》 的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）兰州分公司于近 日通过了兽药GMP验收并取得甘肃省农业农村厅核发的《兽药GMP证书》和《 兽药生产许可证》，具体情况如下： 一、《兽药GMP证书》和《兽药生产许可证》相关信息 1.《兽药GMP证书》 生产范围：细胞悬浮培养口蹄疫病毒灭活疫苗、合成肽疫苗、细胞悬浮培 养病毒灭活疫苗（含细胞悬浮培养病毒亚单位疫苗）（2条）、细胞悬浮培养亚 单位疫苗、细菌灭活疫苗、细胞悬浮培养病毒活疫苗、细菌活疫苗 证号：（2026）兽药GMP证字28001号 企业名称：申联生物医药（上海）股份有限公司兰州分公司 生产地址：甘肃省兰州市兰州新区昆仑山大道中段2398号 验收范围：细胞悬浮培养口蹄疫病毒灭活疫苗、合成肽疫苗、细胞悬浮培 养病毒灭活疫苗（含细胞悬浮培养病毒亚单位疫 ...

Core Viewpoint - The company has successfully passed the veterinary drug GMP acceptance and obtained the Veterinary Drug GMP Certificate and Production License, indicating an expansion in its production capabilities and product range in the vaccine and biological products sector [1][2]. Group 1: GMP Certificate and Production License - The company’s Lanzhou branch has received the Veterinary Drug GMP Certificate, which covers the production of various vaccines including inactivated vaccines for foot-and-mouth disease and live vaccines [1]. - The effective period for both the GMP Certificate and the Production License is from January 14, 2026, to January 13, 2031 [1]. Group 2: Production Capabilities and Product Development - The newly approved production lines for cell suspension culture live vaccines and bacterial live vaccines will be utilized for producing vaccines such as the live vaccine for pseudorabies in pigs and the live vaccine for piglet paratyphoid [1]. - The company is in the process of applying for the veterinary product approval numbers for the pseudorabies live vaccine and the piglet paratyphoid live vaccine to expedite their market launch [1]. - The acquisition of the GMP Certificate and Production License signifies that the production lines meet the regulatory requirements, enhancing the company’s core competitiveness and profitability by diversifying its product offerings [2].

南财智讯1月26日电，申联生物公告，公司兰州分公司于近日通过兽药GMP验收，并取得甘肃省农业农 村厅核发的《兽药GMP证书》（证号：（2026）兽药GMP证字28001号）和《兽药生产许可证》（证 号：兽药生产证字28018号），有效期均为2026年1月14日至2031年1月13日；兰州分公司为申联生物医 药（上海）股份有限公司设立的分支机构，属于公司下属经营实体。本次获证标志着公司细胞悬浮培养 病毒活疫苗及细菌活疫苗等生产线正式具备生产资质，将有助于丰富产品品类、提升产能并加快新疫苗 上市进程。 ...

申联生物表示，2025年度，公司持续拓展生物医药技术应用新领域，多措并举提升产品市场竞争力，公 司营销布局不断优化提升，产品进入大型养殖集团供应链体系取得积极进展，产品销售量增加。但由于 动保行业整体竞争较为激烈，疫苗产品单价下降，导致公司销售收入和毛利率较上年同期均略有下降。 由于客户延迟支付货款导致公司应收账款余额增大，公司计提的信用减值损失上升。另外，随着公司新 疫苗车间投入使用并转固，相关固定资产折旧额增加。 北京商报讯（记者 丁宁）1月23日晚间，申联生物（688098）发布2025年业绩预告显示，公司预计2025 年度实现归属净利润约-2000万元，与上年同期相比，减少亏损约2474万元，亏损幅度同比收窄约 55%。 ...

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

智通财经APP讯，申联生物(688098.SH)发布2025年年度业绩预告，预计2025年度实现归属于母公司所 有者的净利润约-2,000万元，与上年同期相比，减少亏损约2,474万元，亏损幅度同比收窄约55%。 在此情况下，公司适时调整经营策略，市场拓展进一步聚焦客户需求，多联多价疫苗等产品研发取得积 极进展，猪瘟基因工程亚单位疫苗、猪链球菌病/传染性胸膜肺炎二联疫苗等产品接连上市，产品种类 更加丰富;内部管理更加精干高效，期间费用总额较上年同期明显下降，归属母公司净利润亏损减少约 55%。 报告期初，公司投资参股创新药公司扬州世之源生物科技有限责任公司(以下简称"世之源")，世之源正 在开展创新药的临床研究并进行持续投入，对公司净利润造成一定影响。为全面实现人药和动保双主业 协同发展的模式，公司拟收购世之源的控股权，未来公司将以世之源作为新型生物医药技术及人用创新 药推进平台，充分发挥公司前沿生物技术及生产优势在人用创新药领域的延展应用，快速推进艾滋病单 抗等多个创新药的研发及上市。 报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润出现 亏损，主要基于以下原因：202 ...

智通财经APP讯，申联生物(688098.SH)发布2025年年度业绩预告，预计2025年度实现归属于母公司所 有者的净利润约-2,000万元，与上年同期相比，减少亏损约2,474万元，亏损幅度同比收窄约55%。 报告期初，公司投资参股创新药公司扬州世之源生物科技有限责任公司(以下简称"世之源")，世之源正 在开展创新药的临床研究并进行持续投入，对公司净利润造成一定影响。为全面实现人药和动保双主业 协同发展的模式，公司拟收购世之源的控股权，未来公司将以世之源作为新型生物医药技术及人用创新 药推进平台，充分发挥公司前沿生物技术及生产优势在人用创新药领域的延展应用，快速推进艾滋病单 抗等多个创新药的研发及上市。 在此情况下，公司适时调整经营策略，市场拓展进一步聚焦客户需求，多联多价疫苗等产品研发取得积 极进展，猪瘟基因工程亚单位疫苗、猪链球菌病/传染性胸膜肺炎二联疫苗等产品接连上市，产品种类 更加丰富;内部管理更加精干高效，期间费用总额较上年同期明显下降，归属母公司净利润亏损减少约 55%。 报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润出现 亏损，主要基于以下原因：202 ...

公司预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润约-2350万元，与上年同期相 比，减少亏损约2488万元，亏损幅度同比收窄约51%。 格隆汇1月23日丨申联生物(688098.SH)公布，公司预计2025年度实现归属于母公司所有者的净利润 约-2000万元，与上年同期相比，减少亏损约2474万元，亏损幅度同比收窄约55%。 ...